2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5250 Long-term survival prediction in relapsed/refractory B-cell lymphoma treated with CAR-T based on an AI-optimized multimodal model

Hu Qian Jr, Zekai Mao2, Xiaoying Zhang3, Xingcheng Yang4, Juan Peng, MS5, Anqi Zhang6, Jiaqi Guo7, Miao Sun8, Liting Chen, PhD9, Hui Luo10, Li Zhu11, Xiaoxi Zhou12, Yang Yang13, Na Wang, MD, PhD14, Jue Wang15, Wenbin Qian, MD16, Yicheng Zhang17, Jia Wei, MD, PhD18
1 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China
2 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China
3 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China
4 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China
5 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China
6 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China
7 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China
8 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China
9 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China
10 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China
11 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China
12 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China
13 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China
14 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China
15 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China
16 Department of Hematology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
17 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China, Key Laboratory of Organ Transplantation, Ministry of Education; NHC Key Laboratory of Organ Transplantation; Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, Hubei, China
18 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China, Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China, Wuhan, China, Key Laboratory of Organ Transplantation, Ministry of Education; NHC Key Laboratory of Organ Transplantation; Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, Hubei, China

Objective: To identify prognostic biomarkers associated with long-term survival in patients with B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy through integrative omics analysis, with the goal of improving clinical risk stratification and informing precision treatment.

Methods: This multicenter retrospective cohort study included 225 patients with relapsed or refractory (R/R) aggressive B-cell lymphoma who received CAR-T therapy between December 2017 and November 2025. A total of 274 plasma samples were collected at baseline and/or during the peak phase of cytokine release syndrome (CRS) following CAR-T cell infusion. Protein dynamics were characterized using high-throughput proximity extension assays (PEA) and multiplex bead-based cytokine profiling. Kaplan–Meier survival analysis and multivariable Cox proportional hazards regression were performed to identify prognostic biomarkers and develop a survival prediction model, with P < 0.05 considered statistically significant. The training cohort comprised 71 patients, the most recent 123 patients were included as an independent internal validation cohort, and an external validation cohort comprised 17 patients. Patients receiving commercially available CAR-T products met the corresponding approved clinical indications, while participants enrolled in clinical trials provided written informed consent in accordance with the Declaration of Helsinki.

Results: Proteomic analysis revealed significant differences in pathways related to chemokine–integrin signaling, myeloid cell migration, metabolism, and T-cell function between patients with longer survival (≥2 years) and those with shorter survival (<2 years). Absolute quantification further identified 12 significantly differentially expressed proteins, including CCL4, CCL5, and CXCL10, which were predominantly enriched in cytokine activity and chemoattractant activity. A prediction model integrating the International Prognostic Index (IPI) score, complete remission (CR) status at 3 months after CAR-T therapy, and post-CAR-T plasma CCL5 demonstrated good discrimination and calibration, with C-indices of 0.77 in the training cohort, 0.72 in the internal validation cohort, and 0.63 in the external validation cohort. Model-based risk stratification significantly discriminated survival outcomes in the training cohort (P = 0.006) and internal validation cohort (P = 0.015), while the external validation cohort showed a consistent trend toward survival discrimination.

Conclusion: An integrated prediction model incorporating the IPI score, CR status at 3 months after CAR-T therapy, and plasma CCL5 provides a clinically useful approach for survival prediction and risk stratification, potentially supporting individualized treatment decision-making following CAR-T therapy.

Hu Qian Jr: No relevant conflicts of interest to declare.